Latest Updates & News on Current Position Statements & Guidelines
Summary: The Australian Diabetes Society together with the Australian Diabetes Educators Association and Australasian Paediatric Endocrine Group have written the first ever Australian consensus statement on the management of type 2 diabetes in young adults. The consensus statement provides advice on screening, diabetes type, psychological care, lifestyle, glycaemic targets, pharmacological agents, cardiovascular disease risk management, comorbidity assessment, contraception and pregnancy planning, and patient-centred education. Special considerations for Aboriginal and Torres Strait Islander Australians are highlighted separately. The article is published in the MJA. Consensus Statement: Please download the joint full version of the 'ADS-ADEA-APEG Consensus Statement: Management of Type 2 Diabetes in Young Adults (aged 18-30 years)' - PDF (Posted: 18 April, 2022)
Please view the consensus statement via MJA Management of type 2 diabetes in young adults aged 18–30 years: ADS/ADEA/APEG consensus statement | The Medical Journal of Australia (mja.com.au)
The ADS together with ADEA and ANZCA have made an update to the Alert - 'Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor use in People with Diabetes' incorporating recently published data and clinical evidence.
Please download published article in Diabetes Care, Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes | Diabetes Care | American Diabetes Association (diabetesjournals.org) and the alert on periprocedural diabetic ketoacidosis (DKA) with SGLT2i use in people with diabetes developed by ADS, ADEA, DA, NZSSD and ANZCA.
Diabetes Australia’s position statement on Type 2 diabetes remission was jointly developed by a working group from representatives of the Australian Diabetes Society (ADS), the Australian Diabetes Educators Society, provides up-to-date, practical advice and information to people with diabetes and the community about possible remission of type 2 diabetes. It is not intended to be a scientific or fully detailed report for health professionals. People with type 2 diabetes who want to attempt diabetes remission need to do so in close consultation with their diabetes healthcare team, as intensive dietary and weight changes need careful management, monitoring and support. People who do not achieve or sustain remission should not feel that they have ‘failed’. The health benefits of weight loss and a reduction in HbA1c are significant even if remission does not occur, as these reduce the risk of developing diabetes-related complications and may lead to reducing or stopping glucose-lowering medications.
Download the full version of the 'Type 2 Diabetes Remission Position Statement' - PDF (Updated: October, 2021)
Authors: Anthony J Pease, Sofianos Andrikopoulos, Mary B Abraham, Maria E Craig, Brett Fenton, Jane Overland, Sarah price, David Simmons and Glynis P Ross
A consensus statement on 'Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes' was jointly developed by a working group from representatives of the Australian Diabetes Society (ADS), the Australian Diabetes Educators Society (ADEA), the Australasian Paediatric Endocrine Group (APEG), and the Australasian Diabetes in Pregnancy Society (ADIPS) that reflects a national approach to provide best practice across the lifespan for all people living with type 1 diabetes, should have equitable access to the most effective diabetes management systems, including technology where clinically appropriate, regardless of age or concessional status. As diabetes management technologies continue to evolve, so too must management strategies and health care systems. The consensus recommendations should be read in conjunction with the Australian Living Evidence Guidelines in Diabetes.
The ADS/ADEA/APEG/ADIPS Consensus Statement on 'Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes' can be viewed via the Medicial Journal of Australia (MJA) webpage at Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes: consensus statement of the ADS/ADEA/APEG/ADIPS Working Group | The Medical Journal of Australia (mja.com.au)(Published online: 21 June, 2021). Download the consensus statement MJA summary - PDF (Posted: 21 June, 2021)
Please download the joint full version of the ADS/ADEA/APEG/ADIPS Consensus Statement on 'Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes' - PDF (Posted: 21 June, 2021). Please visit the Australian Living Evidence Guidelines in Diabetes webpage at ADS- Living Evidence Guidelines in Diabetes
We have made some important changes and updates to the Australian Type 2 Diabetes Glycaemic Management Algorithm. Download the updated Australian Type 2 Diabetes Glycaemic Management Algorithm - PDF (Posted: 12 October, 2021) or visit the t2d website at https://t2d.diabetessociety.com.au
Download the updated (December, 2016) full version of the 'A New Blood Glucose Management Algorithm for Type 2 Diabetes ADS Position Statement' - PDF (Posted: December, 2016)
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral medications approved for the management of blood glucose levels in type 2 diabetes. Over the last few years there has been an increasing number of reports of patients with type 2 diabetes who are taking SGLT2i developing severe diabetic ketoacidosis (DKA) requiring ICU/HDU admission, particularly during the peri-operative period. Sometimes this DKA is associated with near normal or only mildly elevated blood glucose levels (i.e. euglycaemic ketoacidosis [euDKA]). The risk is increased if the patient has been fasting or has very restricted dietary intake, has undergone bowel preparation, including for colonoscopy and/or a surgical procedure, is dehydrated or has an intercurrent illness such as active infection.
Please download a recent Australian article outlining the risk of euDKA in patients with type 2 diabetes undergoing colonoscopy and the alert on periprocedural diabetic ketoacidosis (DKA) with SGLT2i use developed by ADS, ADEA, DA, NZSSD and ANZCA. View the Alert & full article (Posted: September, 2020)
The Gestational Diabetes in Australia Position Statement has been developed by Diabetes Australia in collaboration with the Australian Diabetes Society, the Australian Diabetes Diabetes Educators Association and the Australasian Diabetes in Pregnancy Society to inform women who may be at risk of, or who develop, gestational diabetes mellitus (GDM) and also to inform the community, policy makers and health care providers. It is not intended as a clinical guidance document for health professionals.
This position statement addresses the diagnosis, management and post-pregnancy care of women who develop GDM. It provides an overview of key issues relating to GDM and its impact and makes recommendations about the care and support women should receive.
There are three main types of diabetes affecting women in pregnancy:
1. pre-existing type 1 diabetes
2. pre-existing type 2 diabetes
3. gestational diabetes (GDM) which is first detected during pregnancy and is different to type 1 diabetes or type 2 diabetes
This position statement only addresses GDM, people with diabetes should always consult a health care professional before making decisions about their diabetes careaa
A joint position statement by the Australian Diabetes Society, Australasian Diabetes Educators Association, Dietitians Association of Australia, Exercise and Sports Science Australia and the Pharmaceutical Society of Australia. Prediabetes has a high prevalence, with early detection essential to facilitate optimal management to prevent the development of conditions such as type 2 diabetes and cardiovascular disease. Prediabetes can include impaired fasting glucose, impaired glucose tolerance and elevated HbA1c. This position statement outlines the approaches to screening and management of prediabetes in primary care - PDF (Posted: May, 2020)
ADS summary of the Prediabetes Position Statement - pdf (Posted June, 2020)
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral medications that promote glucose excretion in the urine for the treatment of type 2 diabetes. Note that SGLT2i are not approved for use in the management of type 1 diabetes in Australia or New Zealand, although they are sometimes used off-label in this setting - PDF (Posted: January, 2020)
Sodium-glucose co-transporter-2 inhibitors(SGLT2i) are being used with increasing frequency due to their effectiveness and also the cardiorenal benefits being demonstrated in clinical trials. Indeed the latter has also led to non-endocrinologists, especially cardiologists and renal physicians commencing the agents. In addition, it is clear that even bowel preparation, not just surgery per se, has been a precipitating factor in a number of cases. Physicians, surgeons, anaesthetists, emergency departments andprimary care providers all need to beaware of the risks of diabetes ketoacidosis with these agents - PDF (Posted: August, 2019)
This Position Statement represents the collective views of the Australian Diabetes Society, the Australian Diabetes Educators Association and Diabetes Australia.The Therapeutic Goods Administration (TGA) recently approved the first “biosimilar” insulin product for use in Australia – Basaglar Insulin. A “biosimilar” is a copy of a biological molecule that has already been approved for use and has a demonstrated similarity in physiological characteristics, efficacy and safety.
Download the full version of the 'Use of “biosimilar” Insulins for Diabetes Position Statement' - PDF (Updated: June, 2019)
Emergency management of hyperglycaemia in primary care was developed by the RACGP and the Australian Diabetes Society (ADS) to raise clinical awareness of hyperglycaemic emergencies in primary care by:
Identifying clinically important patient presentations and risk factors
Ensuring management of hyperglycaemic emergencies is optimised to prevent serious outcomes
This document should be read in conjunction with the relevant management flow charts (Figures 1 and 2), which provide information for the management of hyperglycaemic emergencies before patients arrive at hospital. This position statement should integrate with, but not replace, existing sick day, ambulance and hospital-based management protocols. Clinicians should consult existing local/regional or health pathways/protocols for inpatient management.
It is important to note this statement does not replace existing diagnostic guidelines for routine (non-emergency) presentations, and should not be used for evaluating hyperglycaemia associated with pregnancy where specialist advice on assessment and management must be sought. Download the jointly-produced RACGP and Australian Daibetes Society clinical Position Statement which aims to assess and manage hyperglycaemic emergencies and prevent adverse outcomes - PDF (Posted: May, 2018)
There have been a number of reports of severe euglycaemic ketoacidosis in patients with type 2 diabetes who are taking sodium-glucose co-transporter-2 inhibitors (SGLT2i) during the perioperative period. SGLT2i's are oral medications that promote glucose excretion in the urine for the treatment of type 2 diabetes. Please read the alert for further information about the symptoms and recommendations for practice. If you do have a case of euglycaemic ketoacidosis with SGLT2i inhibitor treatment in your patients with diabetes please ensure that this is reportedas an adverse drug reaction - PDF (Posted: February, 2018)
Authors: Roger Chen, Timothy Lambert, Jen Kinsella, Leon Chapman, Maarten Kamp, Jennifer Conn
The Australian Diabetes Society (ADS) has released a new position statement aimed at improving the management and health outcomes of people living with serious mental illness and type 2 diabetes. A working party, supported by funding from the National Diabetes Services Scheme, was established to provide recommendations for the improvement and to better monitoring of the overall cardiometabolic health, particularly diabetes and diabetes risk, of individuals with serious mental illness.
Download the full version of 'The prevention and management of type 2 diabetes in the context of psychotic disorders ADS Position Statement' - PDF (Posted: October, 2017)
Authors: Mervyn Kyi, Barbora Paldus, Natalie Nanayakkara, Michael Bennett, Rebecca Johnson, Catherine Meehan, Peter Colman
In 2015 the Australian Diabetes Society commissioned a working group to review and revise its position statement on scuba diving in persons with diabetes. The working group consisted of endocrinologists with an interest in type 1 diabetes, diving medical specialists, a recreational diver with diabetes and an advocate for people with type 1 diabetes.
A thorough literature review was performed and all available evidence was summarised and a new position statement was drafted. The new position statement was submitted to the ADS Council for approval.
The scope of this document is restricted to recreational (not professional) diving in line with the available evidence. It is also targeted at insulin-requiring (both type 1 and type 2) diabetes, as traditionally this group has been excluded from recreational diving. This document updates the ADS position statement in line with current evidence.
This website follows the release of a revised position statement by the ADS entitled, ‘A new blood glucose management algorithm for type 2 diabetes’.
This initiative involved the support of groups including the National Association of Diabetes Centres (NADC), Diabetes Australia (DA), the National Prescribing Service (NPS) and the Royal Australian College of General Practitioners (RACGP).
Please visit http://t2d.diabetessociety.com.au to access the T2D treatment website.
The ADS has updated the Type 2 Diabetes Management Algorithm to reflect the new studies reported at the European Society of Cardiology 2020. As of 1 July 2020, the Pharmaceutical Benefits Scheme listed semaglutide (ozempic) for the management of type 2 diabetes in combination with metformin or sulfonylurea or as triple therapy with metformin and sulfonylurea.
Download the updated Blood Glucose Treatment Algorithm for Type 2 Diabetes Evidence Table - PDF (Posted: 03 September, 2020)
Download the updated (December, 2016) full version of the 'A New Blood Glucose Management Algorithm for Type 2 Diabetes ADS Position Statement' - PDF (Posted: December, 2016)
Obesity is a complex and multi-factorial chronic disease with genetic, environmental, physiological and behavioural determinants that requires long-term care. In 2014-15, 63.4% of Australians aged 18 years and over were above normal weight, with 27.9% being obese. Obesity is associated with a broad range of complications including type 2 diabetes, cardiovascular disease, dyslipidaemia, sleep apnoea, osteoarthritis, and certain types of cancers, which significantly impair quality of life. Obesity and its related complications place a considerable financial burden on Australia. In 2014-15, the direct and indirect costs of obesity were estimated at $ 8.65 billion.
This statement has been developed by a working group with representatives from the Australian Diabetes Society, the Australian and New Zealand Obesity Society and the Obesity Surgery Society of Australian and New Zealand.
The aims of the document are to:
1) Assist general practitioners (GPs) in treatment decisions for non-pregnant adults with obesity
2) Provide a practical clinical tool to guide the implementation of existing guidelines for the treatment of obesity in the primary care setting in Australia.
Download the full version of the Australian Obesity Management Algorithm - PDF (Posted: October, 2016)
Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus Postion Statement
The use of glycated haemoglobin (HbA1c) for diagnosis of diabetes mellitus has been accepted by Medicare for reimbursement. The position statement "Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus" has also been published in the MJA on 20 July 2015. Click here to view the document in MJA.(https://www.mja.com.au/journal/2015/203/2/guidance-concerning-use-glycated-haemoglobin-hba1c-diagnosis-diabetes-mellitus)
Like any test, the use of HbA1c for the diagnosis of diabetes mellitus has its strengths and weaknesses. It is important for practitioners to be aware of its potential short comings as well as correctly interpreting a positive and a negative result. The aim of this position paper is to provide a succinct summary of how to optimally use the test to diagnose patients. The test represents an important advance and it is hoped that the guidance provided by this position statement will assist health practitioners to use the test effectively.
Download the full version of the 'Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus ADS Position Statement' - PDF (Posted: July, 2015)
Download the Press Release Statement on 'Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus ADS Position Statement' - PDF (Posted: July, 2015)
View and download the new HbA1c Conversion Table
ADS Recommendations for the use of HbA1c for the Diagnosis of Diabetes
HbA1c is now acceptable as a diagnostic test for diabetes. The threshold for diagnosis is at an HbA1c level of 6.5%. The existing glucose criteria for the diagnosis of diabetes remain valid as well.
The criteria for the diagnosis of diabetes are now:
In an asymptomatic patient the test should be repeated for confirmation of the result and diagnosis. An abnormal result on 2 different diagnostic tests is also acceptable. For full details of the recommendation of HbA1c for the diagnosis of diabetes, including situations where the HbA1c is unreliable, go to https://www.mja.com.au/journal/2012/197/4/role-hba1c-diagnosis-diabetes-mellitus-australia.
Complex environmental, social, behavioral, and emotional factors, known as psychosocial factors, influence living with diabetes, both type 1 and type 2, and achieving satisfactory medical outcomes and psychological well-being. Thus, individuals with diabetes and their families are challenged with complex, multifaceted issues when integrating diabetes care into daily life.
Download the full version of the 'Psychological Care for People with Diabetes: A Position Statement of the American Diabetes Association' - PDF (Posted: December, 2016)
Download the full version of the 'ADS Position Statement on Insulin Glargine (Lantus®) and a Possible Link with Cancer - PDF (Posted: October, 2017)
The ADS has recently endorsed international guidelines that recommend metabolic surgery for patients with type 2 diabetes and class III (BMI ≥40 kg/m2) obesity and patients with type 2 diabetes with class II (BMI 35.0–39.9 kg/m2) obesity who have had inadequate glycaemic control with lifestyle and pharmacotherapy.
Download the full version of the 'Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations' Guidelines - PDF (Posted: October, 2019)
Download the full version of the ADS A New Blood Glucose Management Algorithm for Type 2 Diabetes Position Statement - PDF (Posted: December, 2014)
The Position Statement was also published in the MJA (Med J Aust 2014; 201 (11): 650-653.). You can read the MJA article online.
Download the updated Blood Glucose Treatment Algorithm for Type 2 Diabetes Evidence Table - PDF (Posted: 17 July, 2018)
The 2012 ADS Guidelines for Routine Glucose Control in Hospital have been developed over the last year, and cover a range of areas including general hospital wards, myocardial infarction, stroke, steroid-induced hyperglycaemia, enteral and parenteral feeding, insulin pump therapy, end of life situations, the optimal means for achieving glucose control, routine measures in hospital, and how to follow-up patients with newly discovered hyperglycaemia. The guidelines were informed by systematic reviews and evidence where there was any; otherwise they were based on consensus.
The Writing Party comprised David Chipps, Shirley Cornelius, Barbara Depczynski, Kristine Heels, David O’Neal, Jennifer Wong, Sophia Zoungas, and Wah Cheung.
Download the ADS Guidelines for Routine Glucose Control in Hospital - PDF
These guidelines have been developed by an ADS working group and are primarily intended to provide assistance for those practitioners whose primary focus is not diabetes or who do not have the support of local diabetes expertise in their management of patients with diabetes undergoing surgical procedures.
Download the ADS Peri-operative Diabetes Management Guidelines - PDF
The Australian Diabetes Society (ADS) and the Australasian Paediatric Endocrine Group (APEG) have completed the National Evidence Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults and is approved by the NHMRC under section 14A of the National Health and Medical Research Council Act 1992.
Download the National Evidence Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults - PDF
Download the National Evidence Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults (Technical Report) - PDF
Download the National Evidence Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults (Press Release Document) - PDF
(Please Note: Only electronic PDF copies are available)
The Australian Diabetes Society has produced a Position Statement regarding the individualization of HbA1c targets, for adults with diabetes mellitus. This has been published in the Medical Journal of Australia, in the issue of September 21, 2009. A more comprehensive document with further background documentation can also be downloaded here and you can read the MJA article online.
Posted: May, 2007
You can read the MJA article online.
The National Health & Medical Research Council (NHRMC) Clinical Practice Guidelines Portal can be accessed at http://www.clinicalguidelines.gov.au
All publications relating to Diabetes can be viewed and downloaded from the National Health & Medical Research Council (NHMRC) website at: http://www.nhmrc.gov.au/guidelines/publications/subject/Diabetes
During 2009, five Diabetes Type 2 Guidelines were approved by the Chief Executive Officer (CEO) of NHMRC under Section 14A of the NHMRC Act, namely:
These Guidelines comprise a suite of Type 2 Diabetes Guidelines developed under a funding agreement between the Department of Health and Ageing and the Diabetes Australia Guideline Development Consortium. The most recently finalised Guideline the National Evidence Based Guideline for the Primary Prevention of Type 2 Diabetes, was approved by the NHMRC CEO on 10 December 2009.
The five Guidelines in the series, when combined, present a comprehensive set of evidence-based guidelines for the
prevention, diagnosis and management of Type 2 Diabetes.
The five diabetes guidelines above can be viewed or downloaded at:-
The Australian Diabetes Society has published the following position statements prior to 2001:
The information contained in the ADS Position Statement & Guidelines section and elsewhere on this website is for general information only. It is designed to be educational and is not intended to be and is not a complete or definitive statement on any area of medical practice or procedure. The Society, its directors and other officers make no express or implied warranties, as to suitability for a particular purpose or otherwise, with respect to any information included on this website. Rapid advances in medicine may cause information contained in this website to become outdated or subject to debate. Visitors to this website who are not medical practitioners qualified in the field should seek further professional advice before any action is taken in relation to the matters described or referred to on this website.